The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.